A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas.
Françoise Farace,Françoise Farace,Christophe Massard,Nadege Vimond,Françoise Drusch,N Jacques,Fanny Billiot,Agnès Laplanche,Anne Chauchereau,Ludovic Lacroix,Ludovic Lacroix,David Planchard,S. Le Moulec,Fabrice Andre,Fabrice Andre,Karim Fizazi,Karim Fizazi,J-C. Soria,J-C. Soria,Philippe Vielh +19 more
TLDR
Comparisons of two CTC detection systems based on the expression of the EpCAM antigen or on cell size highlight important discrepancies between the numbers of CTC enumerated by both techniques, especially in patients with metastatic lung carcinoma.Abstract:
BACKGROUND: Circulating tumour cells (CTCs) can provide information on patient prognosis and treatment efficacy. However, there is no universal method to detect CTC currently available. Here, we compared the performance of two CTC detection systems based on the expression of the EpCAM antigen (CellSearch assay) or on cell size (ISET assay). METHODS: Circulating tumour cells were enumerated in 60 patients with metastatic carcinomas of breast, prostate and lung origins using CellSearch according to the manufacturer’s protocol and ISET by studying cytomorphology and immunolabelling with anti-cytokeratin or lineage-specific antibodies. RESULTS: Concordant results were obtained in 55% (11 out of 20) of the patients with breast cancer, in 60% (12 out of 20) of the patients with prostate cancer and in only 20% (4 out of 20) of lung cancer patients. CONCLUSION: Our results highlight important discrepancies between the numbers of CTC enumerated by both techniques. These differences depend mostly on the tumour type. These results suggest that technologies limiting CTC capture to EpCAM-positive cells, may present important limitations, especially in patients with metastatic lung carcinoma.read more
Citations
More filters
Journal ArticleDOI
Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNA
TL;DR: Recent advances in technologies to analyze circulating tumor cells and circulating tumor DNA are setting the stage for real-time, noninvasive monitoring of cancer and providing novel insights into cancer evolution, invasion, and metastasis.
Journal ArticleDOI
Circulating tumor cell technologies
TL;DR: As the understanding of CTC biology matures, CTC technologies will need to evolve, and some of the present challenges facing the field are discussed in light of recent data encompassing epithelial‐to‐mesenchymal transition, tumor‐initiating cells, and CTC clusters.
Journal ArticleDOI
A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire
Nadia Saucedo-Zeni,Steffi Mewes,Robert Niestroj,Lukasz Gasiorowski,David Murawa,Piotr Nowaczyk,Tatiana Tomasi,Ekkehard Weber,Grzegorz Dworacki,Nils G. Morgenthaler,Heike Jansen,Corinna Propping,Karolina Sterzyńska,Wojciech Dyszkiewicz,Maciej Zabel,Marion Kiechle,Ute Reuning,Manfred Schmitt,Klaus Lücke +18 more
TL;DR: The structured medical Seldinger guidewire has the potential to become an important device to enrich CTCs in vivo for monitoring the course of the cancer disease and the efficacy of anticancer treatment.
Journal ArticleDOI
New insights into the role of EMT in tumor immune escape
Stéphane Terry,Pierre Savagner,Sandra Ortiz-Cuaran,Linda Mahjoubi,Pierre Saintigny,Jean Paul Thiery,Jean Paul Thiery,Jean Paul Thiery,Salem Chouaib +8 more
TL;DR: Current knowledge of how cellular heterogeneity and plasticity could be involved in shaping the tumor microenvironment (TME) and in controlling antitumor immunity is reviewed.
Journal ArticleDOI
Detection of Circulating Tumor Cells Harboring a Unique ALK Rearrangement in ALK-Positive Non–Small-Cell Lung Cancer
Emma Pailler,Julien Adam,Amélie Barthelemy,Marianne Oulhen,Nathalie Auger,Alexander Valent,Isabelle Borget,David Planchard,Melissa Taylor,Fabrice Andre,Jean-Charles Soria,Philippe Vielh,Benjamin Besse,Françoise Farace +13 more
TL;DR: The results suggest that CTCs harboring a unique ALK rearrangement and mesenchymal phenotype may arise from clonal selection of tumor cells that have acquired the potential to drive metastatic progression of ALK-positive NSCLC.
References
More filters
Journal ArticleDOI
Epithelial-Mesenchymal Transitions in Development and Disease
Jean Paul Thiery,Jean Paul Thiery,Hervé Acloque,Ruby Yun-Ju Huang,Ruby Yun-Ju Huang,M. Angela Nieto +5 more
TL;DR: The mesenchymal state is associated with the capacity of cells to migrate to distant organs and maintain stemness, allowing their subsequent differentiation into multiple cell types during development and the initiation of metastasis.
Journal ArticleDOI
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Massimo Cristofanilli,G. Thomas Budd,Matthew J. Ellis,Alison Stopeck,Jeri Matera,M. Craig Miller,James M. Reuben,Gerald V. Doyle,W. Jeffrey Allard,Leon W.M.M. Terstappen,Daniel F. Hayes +10 more
TL;DR: The number of circulating tumor cells before treatment is an independent predictor of progression-free survival and overall survival in patients with metastatic breast cancer.
Journal ArticleDOI
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
TL;DR: Owing to the importance of these tumour-associated phenotypes in metastasis and cancer-related mortality, targeting the products of such cellular plasticity is an attractive but challenging approach that is likely to lead to improved clinical management of cancer patients.
Journal ArticleDOI
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.
W. Jeffrey Allard,Jeri Matera,M. Craig Miller,Madeline Repollet,Mark Connelly,Chandra Rao,Arjan G.J. Tibbe,Jonathan W. Uhr,Leon W.M.M. Terstappen +8 more
TL;DR: The CellSearch system can be standardized across multiple laboratories and may be used to determine the clinical utility of CTCs, which are extremely rare in healthy subjects and patients with nonmalignant diseases but present in various metastatic carcinomas with a wide range of frequencies.
Journal ArticleDOI
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono,Howard I. Scher,R. Bruce Montgomery,Chris Parker,M. Craig Miller,H. Tissing,Gerald V. Doyle,Leon W.W.M. Terstappen,Kenneth J. Pienta,Derek Raghavan +9 more
TL;DR: CTC are the most accurate and independent predictor of OS in CRPC, and this data led to Food and Drug Administration clearance of this assay for the evaluation of CRPC.
Related Papers (5)
Isolation of rare circulating tumour cells in cancer patients by microchip technology.
Isolation of circulating tumor cells using a microvortex-generating herringbone-chip
Shannon L. Stott,Chia-Hsien Hsu,Chia-Hsien Hsu,Chia-Hsien Hsu,Dina Tsukrov,Min Yu,David T. Miyamoto,Belinda A. Waltman,S. Michael Rothenberg,Ajay Shah,Malgorzata E. Smas,George K. Korir,Frederick P. Floyd,Anna J. Gilman,Jenna B. Lord,Daniel Winokur,Simeon Springer,Daniel Irimia,Daniel Irimia,Sunitha Nagrath,Sunitha Nagrath,Lecia V. Sequist,Lecia V. Sequist,Richard T. Lee,Richard T. Lee,Kurt J. Isselbacher,Shyamala Maheswaran,Daniel A. Haber,Daniel A. Haber,Mehmet Toner,Mehmet Toner +30 more